'Sick or Treat: eCancer by Dr Nick Chapman Sick or Treat Sessions
-
Upload
rarecancersaustralia -
Category
Health & Medicine
-
view
222 -
download
0
Transcript of 'Sick or Treat: eCancer by Dr Nick Chapman Sick or Treat Sessions
Sick or Treat: eCancerLessons from the world of neglected disease R&D
Dr Nick ChapmanDirector of Research, Policy Cures
Sydney, 28 October 2015
Comparing global investment in R&D
All health R&D $270bn
Cancer$15bn
Rare cancers$3.0bn? Neglected diseases
$3.2bn
Solutions for neglected disease R&D
• Public and philanthropic funding
• Product Development Partnerships
• Other innovative mechanisms
Public and philanthropic funding
Two thirds from top 3 funders:
- US NIH (39%)
- Gates Foundation (16%)
- Pharma industry (12%)
Product Development Partnerships (PDPs)
PDPs are involved in 40% of all pipeline candidates
… despite managing only 15% of total funding for
neglected disease R&D in 2013
Target Product Profiles – focus on patient needs from the outset (incl. max acceptable price)
Other incentives
• Priority Review Vouchers
• Global Health Innovative Technologies fund
• Global Health Investment Fund
These approaches have helped grow the ND R&D pipeline…
The R&D pipeline for neglected diseases is healthier now than it has ever been
485product candidates in the pipeline
2004 2012 2015
215?
365
485
… but less for the ‘most neglected’ – just as for rarest
Highly concentrated on just three diseases (malaria, TB, and HIV/AIDS)
Malaria Tubercu-losis HIV/AIDS
Kine-toplas-
tids
Diarrhoeal diseases
Helminth infections
Hepatitis C
All other diseases
combined
67%